BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] T-helper 1 versus T-helper 2 lymphocyte immunodysregulation is the central factor in genesis of Burkitt lymphoma: hypothesis.

BACKGROUND: The HIV epidemic has challenged our previous understanding of endemic Burkitt's lymphoma.

Despite the strong association of Burkitt's lymphoma and HIV infection in the Developed world, and against previous postulations that the cancer is due to immunosupression among African children, the HIV epidemic in the Malaria belt has not been associated with a corresponding increase in incidence of childhood Burkitt's lymphoma.

Even outside the context of HIV infection, there is substantial evidence for a strong but skewed immune response towards a TH2 response in genesis of Burkitt lymphoma.

PRESENTATION OF THE HYPOTHESIS: Rather than a global and/or profound immunosupression, the final common pathway in genesis of Burkitt's lymphoma is the dysregulation of the immune response towards a TH2 response dominated by B-lymphocytes, and the concomitant suppression of the TH1 cell-mediated immune surveillance, driven by various viral/parasitic/bacterial infections.

TESTING THE HYPOTHESIS: Case control studies comparing TH2 and TH1 immune responses in Burkitt lymphoma of different etiological types (sporadic, HIV-related, endemic and post-transplant) to demonstrate significant dominance of TH2 immune response in presence of poor CMI response as a common factor.

Immunological profiling to evaluate differences between immune states that are associated (such as recurrent Malaria infection) and those that are not associated (such as severe protein-energy malnutrition) with Burkitt lymphoma.

Prospective cohorts profiling chronology of immunological events leading to Burkitt lymphoma in children with EBV infection.

IMPLICATIONS OF THE HYPOTHESIS: The dysregulation of the immune response may be the missing link in our understanding of Burkitt lymphomagenesis.

HIV InSite. treatment guidelines - Malaria and HIV .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] IARC Sci Publ. 1985;(60):177-86 [3905588.001]

[Cites] P N G Med J. 1986 Mar;29(1):41-3 [3019040.001]

[Cites] Proc R Soc Med. 1971 Sep;64(9):909-10 [4329792.001]

[Cites] Clin Exp Immunol. 1984 May;56(2):371-6 [6329564.001]

[Cites] Prog Food Nutr Sci. 1984;8(3-4):193-228 [6396715.001]

[Cites] Fed Proc. 1980 Nov;39(13):3098-104 [6968692.001]

[Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]

[Cites] Arch Dis Child. 1995 Aug;73(2):100-4; discussion 104-5 [7574850.001]

[Cites] Immunol Rev. 1994 Aug;140:73-92 [7821929.001]

[Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]

[Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]

[Cites] AIDS. 1996 Jun;10(6):643-7 [8780819.001]

[Cites] Am J Pathol. 1976 Sep;84(3):599-614 [8988.001]

[Cites] Ann Oncol. 1997 Oct;8(10):987-94 [9402172.001]

[Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]

[Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]

[Cites] Cent Afr J Med. 1998 Oct;44(10):242-5 [10101432.001]

[Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]

[Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]

[Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]

[Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]

[Cites] J Gen Virol. 2001 Dec;82(Pt 12):3051-5 [11714983.001]

[Cites] J Natl Cancer Inst. 1976 Mar;56(3):479-83 [1255780.001]

[Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]

[Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]

[Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]

[Cites] Int J Immunopharmacol. 1992 Apr;14(3):361-6 [1618590.001]

[Cites] Mol Immunol. 2007 Feb;44(5):934-42 [16730063.001]

[Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]

[Cites] Transplantation. 2006 Oct 27;82(8):1013-23 [17060848.001]

[Cites] Eur J Cancer Prev. 2007 Feb;16(1):55-61 [17220705.001]

[Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]

[Cites] Int J Cancer. 1990 Apr 15;45(4):650-3 [2323841.001]

[Cites] Paediatr Perinat Epidemiol. 1990 Jul;4(3):303-24 [2374749.001]

[Cites] Am J Epidemiol. 1989 Apr;129(4):740-52 [2923122.001]

[Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]

(PMID = 17509139.001).

[ISSN] 1750-9378

[Journal-full-title] Infectious agents and cancer

[ISO-abbreviation] Infect. Agents Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC1884132

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.

Prognosis of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma has improved since the introduction of highly active antiretroviral therapy.

Burkitt lymphomas (BLs) still have poor outcome in patients with bone marrow (BM) or central nervous system (CNS) involvement when treated with standard-dose chemotherapy.

We have prospectively evaluated the LMB86 regimen in 63 human immunodeficiency virus (HIV)-infected patients with stage IV (BM and/or CNS involvement) BL consecutively recruited between November 1992 and January 2006.

At BL diagnosis, the median CD4 cell count was 239 x 10(6)/L (range, 16-1188 x 10(6)/L).

Seven treatment-related deaths occurred and all patients experienced severe BM toxicity.

We conclude that LMB86 regimen is highly effective in advanced HIV-related BL and should be proposed for patients with CD4 count higher than 200 x 10(6)/L or ECOG of 2 or less.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17609431.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Burkitt's lymphoma of the caecum in a patient with AIDS: clinical case and review of the literature].

[Transliterated title] Linfoma di Burkitt del cieco in paziente con AIDS conclamato: caso clinico e revisione della letteratura.

The incidence of primary colic lymphoma, above all in the non-Hodgkin variant, is clearly higher in the HIV positive population, especially in subjects with AIDS.

The authors present the case of a 51-year-old patient with AIDS undergoing antiviral therapy; he was suffering from abdominal pain and presented a palpable mass in the right iliac fossa; diagnosis was caecal non-Hodgkin lymphoma (NHL); radical right hemicolectomy was carried out with definitive histological diagnosis of Burkitt-type small cell NHL.

Nevertheless such cases are comparatively frequent in patients with HIV virus, especially in the active phase and clinically proven to be due to immunodeficient syndrome.

Of cardinal importance is the differential diagnosis between primary and secondary forms because of the different treatment and prognosis.

Frequently such forms are observed in patients with AIDS, at advanced stages and with differentiated and hence more aggressive histotypes, also because they are present in organisms weakened by the underlying disease and by immunodeficiency.

Primary NHLs of the colon are relatively frequent and aggressive in patients with AIDS; early diagnosis and treatment are therefore of fundamental importance to improve the oncological outcome for these patients.

[MeSH-major] Burkitt Lymphoma. Cecal Neoplasms. Immunocompromised Host. Lymphoma, AIDS-Related

[MeSH-minor] Abdominal Pain / etiology. Diagnosis, Differential. HIV-1 / isolation & purification. Humans. Male. Middle Aged. Treatment Outcome

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19365324.001).

[ISSN] 0026-4733

[Journal-full-title] Minerva chirurgica

[ISO-abbreviation] Minerva Chir

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] Italy

[Number-of-references] 22

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Association between meningeal Burkitt lymphoma and Epstein-Barr virus in an HIV-infected patient].

[Transliterated title] Asociación de linfoma de Burkitt meníngeo y virus de Epstein-Barr en paciente infectada por el VIH.

[MeSH-major] Burkitt Lymphoma / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology. Meningeal Neoplasms / virology. Spinal Cord Compression / etiology. Spinal Neoplasms / virology

Genetic Alliance. consumer health - HIV.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18053481.001).

[ISSN] 0213-005X

[Journal-full-title] Enfermedades infecciosas y microbiología clínica

[ISO-abbreviation] Enferm. Infecc. Microbiol. Clin.

[Language] spa

[Publication-type] Case Reports; Letter

[Publication-country] Spain

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fatal adenovirus pneumonia in a person with AIDS and Burkitt lymphoma: a case report and review of the literature.

Although adenoviruses are a recognized cause of serious pulmonary and disseminated disease among stem cell transplant recipients, their importance in other immunocompromised patient populations is less clearly documented.

We present a case of a person with AIDS who was receiving chemotherapy for Burkitt lymphoma in whom fatal adenovirus pneumonia and adenoviremia developed, and we review the published literature on adenovirus infection in the setting of HIV disease.

[MeSH-major] Acquired Immunodeficiency Syndrome. Adenoviridae Infections. Burkitt Lymphoma / drug therapy. HIV-1. Lymphoma, AIDS-Related / drug therapy. Pneumonia, Viral

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18472442.001).

[ISSN] 1053-0894

[Journal-full-title] The AIDS reader

[ISO-abbreviation] AIDS Read

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antiviral Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Recent advances and the treatment strategies of AIDS-related malignant lymphoma].

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related

[MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Burkitt Lymphoma / therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy. Humans. Lymphoma, Non-Hodgkin / therapy. Prednisone / administration & dosage. Rituximab. Transplantation, Autologous. Vincristine / administration & dosage

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18833933.001).

[ISSN] 0485-1439

[Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology

[ISO-abbreviation] Rinsho Ketsueki

[Language] jpn

[Publication-type] Journal Article; Review

[Publication-country] Japan

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 11056-06-7 / Bleomycin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ACVB protocol; CHOP protocol

[Number-of-references] 92

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intraoral diffuse large B-cell lymphoma with Burkitt-like morphology in an HIV-positive patient--a diagnostic dilemma.

[MeSH-major] Burkitt Lymphoma / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Maxillary Neoplasms / pathology

[MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Male. Maxillary Sinus Neoplasms / pathology. Middle Aged

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20591554.001).

[ISSN] 1531-5053

[Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons

[ISO-abbreviation] J. Oral Maxillofac. Surg.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] EBV and HIV-Related Lymphoma.

HIV-associated lymphoproliferative disorders represent a heterogeneous group of diseases, arising in the presence of HIV-associated immunodeficiency.

The overall prevalence of HIV-associated lymphoma is significantly higher compared to that of the general population and it continues to be relevant even after the wide availability of highly active antiretroviral therapy (HAART) (1).

It has been largely implicated in the development of B-cell lymphoproliferative disorders as Burkitt lymphoma (BL), Hodgkin disease (HD), systemic non Hodgkin lymphoma (NHL), primary central nervous system lymphoma (PCNSL), nasopharyngeal carcinoma (NC).

Virus-associated lymphomas are becoming of significant concern for the mortality of long-lived HIV immunocompromised patients, and therefore, research of advanced strategies for AIDS-related lymphomas is an important field in cancer chemotherapy.

Detailed understanding of the EBV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy The linkage of HIV-related lymphoma with EBV infection of the tumor clone has several pathogenetic, prognostic and possibly therapeutic implications which are reviewed herein.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Semin Oncol. 1999 Jun;26(3):346-56 [10375091.001]

[Cites] Blood. 2001 Jul 1;98(1):146-55 [11418474.001]

[Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]

[Cites] J Exp Med. 2001 Dec 17;194(12):1731-41 [11748275.001]

[Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]

[Cites] Nat Med. 2002 Apr;8(4):319-23 [11927927.001]

[Cites] AIDS. 2002 May 24;16(8):1195-6 [12004285.001]

[Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]

[Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15572-7 [12434018.001]

[Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]

[Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]

[Cites] Cancer Res. 2003 Jun 1;63(11):2982-9 [12782607.001]

[Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]

[Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]

[Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]

[Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]

[Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]

[Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]

[Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]

[Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]

[Cites] Am J Hematol. 2008 Oct;83(10):763-4 [18756546.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] J Exp Med. 1986 Dec 1;164(6):2049-60 [3491176.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] J Clin Oncol. 1993 Sep;11(9):1674-81 [8394878.001]

[Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]

[Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]

[Cites] J Exp Med. 1991 Jan 1;173(1):147-58 [1845872.001]

[Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]

[Cites] Am J Hematol. 1989 Nov;32(3):200-4 [2816914.001]

[Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]

[Cites] J Clin Oncol. 1995 Jul;13(7):1758-67 [7541452.001]

[Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]

[Cites] J Virol. 1996 Feb;70(2):1143-53 [8551575.001]

[Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]

[Cites] Curr Opin Oncol. 1996 Sep;8(5):373-6 [9026061.001]

[Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]

[Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]

[Cites] Neurology. 2000 Feb 22;54(4):993-7 [10691003.001]

[Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]

[Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]

[Cites] J Clin Invest. 1997 Apr 1;99(7):1525-33 [9119996.001]

[Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]

[Cites] J Clin Pathol. 1997 Nov;50(11):911-8 [9462239.001]

[Cites] Am J Pathol. 1998 Mar;152(3):623-30 [9502401.001]

[Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]

[Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]

[Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]

[Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]

[Cites] AIDS. 2002 Oct 18;16(15):2001-11 [12370498.001]

[Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]

[Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]

[Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]

[Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]

[Cites] Am J Hematol. 2003 Jul;73(3):143-8 [12827649.001]

[Cites] Cancer. 2003 Jul 15;98(2):300-9 [12872349.001]

[Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]

[Cites] Am J Hematol. 2004 May;76(1):88-91 [15114607.001]

[Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]

[Cites] Neurology. 1997 Mar;48(3):687-94 [9065549.001]

[Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]

[Cites] Presse Med. 2004 Dec 4;33(21):1487-92 [15637794.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]

[Cites] Clin Infect Dis. 2005 Oct 15;41(8):e76-9 [16163622.001]

[Cites] Hematol Oncol. 2005 Jun;23(2):61-7 [16216037.001]

[Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]

[Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]

[Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]

[Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]

[Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]

[Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]

[Cites] Adv Anat Pathol. 2007 May;14(3):189-94 [17452815.001]

[Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]

[Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]

[Cites] Blood Rev. 2008 Sep;22(5):261-81 [18456377.001]

[Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]

[Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52 [9037073.001]

[Cites] AIDS. 1997 Oct;11(12):1522-3 [9342077.001]

[Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]

[Cites] J Natl Cancer Inst. 1998 Mar 4;90(5):364-9 [9498486.001]

[Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]

[Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]

[Cites] Immunity. 1998 Sep;9(3):405-11 [9768760.001]

[Cites] Am J Pathol. 1998 Nov;153(5):1609-14 [9811353.001]

[Cites] AIDS. 2001 Nov 9;15(16):2119-27 [11684931.001]

[Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]

[Cites] Dermatology. 2004;208(3):287-90 [15118393.001]

[Cites] Clin Infect Dis. 2004 Jun 1;38(11):1629-32 [15156453.001]

[Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]

[Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]

[Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]

[Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]

[Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]

[Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]

[Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]

[Cites] Crit Rev Oncog. 1998;9(3-4):199-208 [10201628.001]

(PMID = 21416008.001).

[ISSN] 2035-3006

[Journal-full-title] Mediterranean journal of hematology and infectious diseases

[ISO-abbreviation] Mediterr J Hematol Infect Dis

[Language] eng

[Publication-type] Journal Article

[Publication-country] Italy

[Other-IDs] NLM/ PMC3033170

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] RB and cell cycle progression.

The Rb protein is a tumor suppressor, which plays a pivotal role in the negative control of the cell cycle and in tumor progression.

It has been shown that Rb protein (pRb) is responsible for a major G1 checkpoint, blocking S-phase entry and cell growth.

Loss of pRb functions may induce cell cycle deregulation and so lead to a malignant phenotype.

Functional inactivation of pRb by viral oncoprotein binding is also shown in many neoplasias such as cervical cancer, mesothelioma and AIDS-related Burkitt's lymphoma.

[MeSH-major] Cell Cycle / genetics. Retinoblastoma Protein / genetics

[MeSH-minor] Cell Division / genetics. Chromosome Mapping. Chromosomes, Human, Pair 13. Genes, Tumor Suppressor. Humans. Transcription, Genetic. Tumor Suppressor Proteins / genetics

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16936740.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Chemical-registry-number] 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins

[Number-of-references] 86

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genome wide DNA-profiling of HIV-related B-cell lymphomas.

Non-Hodgkin lymphomas (NHL) represent a frequent complication of human immunodeficiency virus (HIV) infection.

To elucidate HIV-NHL pathogenesis, we performed a genome-wide DNA profiling based on a single nucleotide polymorphism-based microarray comparative genomic hybridization in 57 HIV-lymphomas and, for comparison, in 105 immunocompetent diffuse large B-cell lymphomas (IC-DLBCL).

HIV-Burkitt lymphoma showed a significantly lower number of lesions than HIV-DLBCL (P = 0.032), whereas the median number of copy number changes was significantly higher in Epstein-Barr virus negative (EBV-) HIV-DLBCL (42.5, range 8-153) compared to EBV+ cases (22; range 3-41; P = 0.029).

Fragile sites-associated genes, including FHIT (FRA3B), WWOX (FRA16D), DCC (FRA18B) and PARK2 (FRA6E) were frequently inactivated in HIV-NHL by interstitial deletions, and a significantly higher prevalence of FHIT alterations was observed in HIV-DLBCL compared to IC-DLBCL.

[MeSH-major] Lymphoma, AIDS-Related / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Polymorphism, Single Nucleotide

[MeSH-minor] Burkitt Lymphoma / genetics. Chromosome Aberrations. DNA Methylation. Gene Frequency. Humans. Microarray Analysis. Polymerase Chain Reaction / methods

Genetic Alliance. consumer health - B-Cell Lymphomas.

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oncogene. 2004 Dec 2;23(56):9148-54 [15480422.001]

[Cites] Br J Haematol. 2006 Jul;134(1):27-36 [16803564.001]

[Cites] Cancer Lett. 2006 Jan 28;232(1):37-47 [16242840.001]

[Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]

[Cites] Semin Cancer Biol. 2007 Feb;17(1):31-41 [17140807.001]

[Cites] Cancer Lett. 2007 Jul 18;252(2):157-70 [17188425.001]

[Cites] Blood. 2003 Nov 15;102(10):3775-85 [12907442.001]

[Cites] Blood. 2008 Feb 15;111(4):2347-53 [18079361.001]

[Cites] Cancer Lett. 2006 Jan 28;232(1):48-57 [16221525.001]

[Cites] Am J Hum Genet. 1992 Jun;50(6):1243-51 [1317992.001]

[Cites] Haematologica. 2008 Aug;93(8):1178-85 [18556404.001]

[Cites] J Biol Chem. 2006 Mar 31;281(13):8591-9 [16455660.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3615-20 [11891319.001]

[Cites] AIDS. 2006 Nov 28;20(18):2285-91 [17117014.001]

[Cites] Int J Cancer. 2005 Sep 1;116(3):407-14 [15818620.001]

[Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]

[Cites] J Cell Physiol. 2007 Aug;212(2):307-10 [17458891.001]

[Cites] Oncogene. 2003 Feb 27;22(8):1225-37 [12606949.001]

[Cites] Mol Cancer Res. 2003 Nov;1(13):940-7 [14638866.001]

[Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] Front Biosci. 2007 Sep 01;12:4911-24 [17569619.001]

[Cites] Blood. 2006 Mar 15;107(6):2477-85 [16317097.001]

[Cites] Cancer Res. 2004 Sep 1;64(17):5948-55 [15342373.001]

[Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]

[Cites] Nat Cell Biol. 2003 Mar;5(3):216-23 [12598906.001]

[Cites] Nature. 2009 Jun 4;459(7247):717-21 [19412164.001]

[Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]

[Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]

[Cites] PLoS Comput Biol. 2006 May;2(5):e41 [16699594.001]

[Cites] Nat Rev Cancer. 2004 Dec;4(12):978-87 [15573119.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1270-5 [11423258.001]

[Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1129-36 [17823927.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]

[Cites] Cancer Res. 2008 Apr 15;68(8):2610-21 [18375840.001]

[Cites] Cell Cycle. 2007 May 2;6(9):1044-8 [17457056.001]

[Cites] BMC Bioinformatics. 2009 Jan 08;10:10 [19133123.001]

[Cites] Int J Cancer. 2006 Apr 15;118(8):1945-53 [16287063.001]

[Cites] Cancer Res. 2001 Nov 15;61(22):8068-73 [11719429.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]

[Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1031-6 [11355876.001]

[Cites] Genes Chromosomes Cancer. 2004 Dec;41(4):321-9 [15384174.001]

[Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10 ):5956-61 [12719539.001]

[Cites] Nat Rev Immunol. 2009 Apr;9(4):235-45 [19319142.001]

[Cites] Br J Haematol. 2008 May;141(5):622-30 [18397341.001]

[Cites] Oncogene. 2005 Feb 24;24(9):1625-33 [15674328.001]

[Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]

[Cites] Lab Invest. 2004 Sep;84(9):1193-9 [15241441.001]

[Cites] Cell Death Differ. 2005 Aug;12(8):1031-43 [16015380.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3949-54 [17360458.001]

[Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]

[Cites] Cancer Genet Cytogenet. 2006 Dec;171(2):119-21 [17116491.001]

[Cites] J Neurochem. 2008 Jun;105(5):1806-19 [18248624.001]

(PMID = 19832807.001).

[ISSN] 1365-2141

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / U01 CA114778; United States / NCI NIH HHS / CA / U01 CA114778-05; United States / NCI NIH HHS / CA / UO1 CA 114778

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Germinal center and activated b-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases.

Morphologic features of Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) overlap.

We tested a panel of 8 germinal center (GC) and activated B-cell (ABC) markers for their ability to separate BL and DLBCL.

We diagnosed 16 BL and 39 DLBCL cases from 21 patients with AIDS and 34 without AIDS based on traditional morphologic criteria, Ki-67 proliferative index, and c-myc rearrangement (fluorescence in situ hybridization).

Hierarchical clustering yielded 2 major clusters significantly associated with morphologic diagnosis (P < .001).

This revealed a high-GC/low-ABC group and a low-GC/high-ABC group that were associated significantly with morphologic diagnosis (P < .001).

[MeSH-major] B-Lymphocytes / immunology. Burkitt Lymphoma / pathology. Germinal Center / immunology. Lymphoma, AIDS-Related / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

[MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymphocyte Activation. Male. Middle Aged. Retrospective Studies

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16203284.001).

[ISSN] 0002-9173

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Ward round--Recurrent anemia and infection in an HIV-positive woman. Burkitt's lymphoma.

[MeSH-major] Anemia / complications. Burkitt Lymphoma / complications. HIV Infections / complications. HIV Seropositivity / complications. Lymphoma, Non-Hodgkin / complications

[MeSH-minor] Adult. Antineoplastic Agents, Hormonal / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Lymphoma, AIDS-Related / therapy. Palliative Care / methods. Prognosis. Recurrence

Genetic Alliance. consumer health - Anemia.

Genetic Alliance. consumer health - HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - Anemia.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

HIV InSite. treatment guidelines - Symptom Management .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Hazardous Substances Data Bank. DEXAMETHASONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Haematologica. 2005 Jul;90(7):990-2 [15996943.001]

[Cites] Lancet Oncol. 2008 Jun;9(6):512-3 [18510986.001]

[Cites] PLoS One. 2008;3(6):e2505 [18560562.001]

[Cites] Lancet Oncol. 2008 Jul;9(7):683-92 [18598933.001]

[Cites] Br J Haematol. 2001 Mar;112(4):900-8 [11298584.001]

[Cites] East Afr Med J. 2001 Jul;78(7):349-54 [11957257.001]

[CommentIn] Malawi Med J. 2010 Jun;22(2):59-60 [21618748.001]

(PMID = 20345012.001).

[ISSN] 1995-7262

[Journal-full-title] Malawi medical journal : the journal of Medical Association of Malawi

[ISO-abbreviation] Malawi Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] Malawi

[Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone

[Other-IDs] NLM/ PMC3345734

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.

The ML frequency, pathogenicity, clinical patterns and possible association with AIDS in Tanzania, are not well documented impeding the development of preventive and therapeutic strategies.

METHODS: Sections of 176 archival formalin-fixed paraffin-embedded biopsies of ML patients at Muhimbili National Hospital (MNH)/Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania from 1996-2001 were stained for hematoxylin and eosin and selected (70) cases for expression of pan-leucocytic (CD45), B-cell (CD20), T-cell (CD3), Hodgkin/RS cell (CD30), histiocyte (CD68) and proliferation (Ki-67) antigen markers.

RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD).

Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.

CONCLUSION: Malignant lymphomas apparently, increased significantly among diagnosed tumors at MNH between 1996 and 2001, predominantly among the young, HIV infected and AIDS patients.

The frequent aggressive clinical and histological presentation as well as the dominant B-immunophenotype and the HIV serology indicate a pathogenic association with AIDS.

Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.

[MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Med Clin (Barc). 2000 Jan 15;114(1):19-21 [10782456.001]

[Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]

[Cites] Med Trop (Mars). 1999;59(4 Pt 2):499-502 [10901854.001]

[Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]

[Cites] Curr Opin Oncol. 2000 Sep;12(5):383-94 [10975544.001]

[Cites] Med Oncol. 2001;18(1):15-22 [11778965.001]

[Cites] AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):383-90 [11897040.001]

[Cites] East Afr Med J. 2000 Aug;77(8):435-9 [12862069.001]

[Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]

[Cites] East Afr Med J. 1966 Jul;43(7):274-83 [5911333.001]

[Cites] Br Med Bull. 1971 Jan;27(1):14-20 [5100946.001]

[Cites] Cancer. 1980 Jul 1;46(1):186-9 [6893012.001]

[Cites] Acta Pathol Microbiol Scand A. 1981 Nov;89(6):417-24 [6278823.001]

[Cites] East Afr Med J. 1982 Apr;59(4):256-60 [7140611.001]

[Cites] Ann Trop Paediatr. 1984 Jun;4(2):83-5 [6083750.001]

[Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]

[Cites] Cancer. 1991 Apr 1;67(7):1865-73 [2004300.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]

[Cites] Curr Opin Oncol. 1994 Sep;6(5):489-91 [7827151.001]

[Cites] Semin Diagn Pathol. 1997 Feb;14(1):48-53 [9044509.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]

[Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]

[Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]

[Cites] Blood. 1999 Feb 15;93(4):1364-71 [9949180.001]

[Cites] Bull Cancer. 1999 Jun;86(6):529-36 [10417426.001]

[Cites] J Pak Med Assoc. 1999 Jan;49(1):11-5 [10463009.001]

[Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]

[Cites] East Afr Med J. 2004 Aug;(8 Suppl):S63-7 [15622604.001]

[Cites] East Afr Med J. 2004 Aug;(8 Suppl):S90-6 [15622607.001]

[Cites] East Afr Med J. 2004 Aug;81(8):384-7 [15622930.001]

[Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]

[Cites] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]

[Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]

[Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]

[Cites] Curr HIV/AIDS Rep. 2005 Aug;2(3):146-53 [16091262.001]

[Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]

[Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]

[Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]

[Cites] Oncol Rep. 2007 Jun;17(6):1291-9 [17487381.001]

[Cites] Int J Cancer. 2007 Oct 15;121(8):1806-12 [17557295.001]

[Cites] Cancer Sci. 2008 Feb;99(2):345-9 [18201268.001]

[Cites] Malays J Pathol. 1999 Jun;21(1):45-50 [10879278.001]

(PMID = 18577266.001).

[ISSN] 1756-9966

[Journal-full-title] Journal of experimental & clinical cancer research : CR

[ISO-abbreviation] J. Exp. Clin. Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Other-IDs] NLM/ PMC2438337

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV infection and lymphoma.

The incidence of lymphoma in patients with HIV infection greatly exceeds that of the general population.

The increased risk for lymphoma appears related to multiple factors, including the transforming properties of the retrovirus itself, the immunosuppression and cytokine dysregulation that results from the disease, and, most importantly, opportunistic infections with other lymphotrophic herpes viruses such as Epstein-Barr virus and human herpesvirus 8.

However, following the introduction of highly active antiretroviral therapy, the risk for developing lymphoma in the context of HIV infection has decreased and the clinical outcome has improved.

[MeSH-major] Lymphoma, AIDS-Related / pathology

[MeSH-minor] Burkitt Lymphoma / immunology. Burkitt Lymphoma / pathology. Burkitt Lymphoma / virology. Hodgkin Disease / immunology. Hodgkin Disease / pathology. Hodgkin Disease / virology. Humans. Immunocompetence. Immunocompromised Host. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / virology

Genetic Alliance. consumer health - HIV.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] AIDS. 2002 Sep 6;16(13):1803-7 [12218393.001]

[Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]

[Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]

[Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]

[Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]

[Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]

[Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]

[Cites] Am J Otolaryngol. 1999 Jan-Feb;20(1):56-8 [9950115.001]

[Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]

[Cites] Int J Dermatol. 1999 Feb;38(2):111-8 [10192159.001]

[Cites] Am J Surg Pathol. 1999 May;23(5):519-22 [10328082.001]

[Cites] Am J Surg Pathol. 1999 May;23(5):560-6 [10328088.001]

[Cites] Blood. 1999 Jul 1;94(1):275-82 [10381523.001]

[Cites] J Clin Pathol. 1999 Apr;52(4):313-6 [10474529.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

[Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]

[Cites] AIDS Res Hum Retroviruses. 2004 Feb;20(2):129-33 [15018699.001]

[Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]

[Cites] Am J Hematol. 2004 May;76(1):88-91 [15114607.001]

[Cites] Dermatology. 2004;208(3):287-90 [15118393.001]

[Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1020-7 [15247554.001]

[Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]

[Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]

[Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]

[Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]

[Cites] Cancer. 1988 Jun 1;61(11):2325-37 [3365660.001]

[Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]

[Cites] Am J Hematol. 1989 Nov;32(3):200-4 [2816914.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]

[Cites] J Clin Oncol. 1992 Mar;10(3):383-9 [1311023.001]

[Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]

[Cites] Am J Epidemiol. 1994 Feb 15;139(4):362-8 [8109570.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] Curr Opin Oncol. 1994 Sep;6(5):492-6 [7827152.001]

[Cites] Am J Surg Pathol. 1995 Mar;19(3):357-63 [7872434.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] N Engl J Med. 1996 Jul 4;335(1):61-2 [8637555.001]

[Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]

[Cites] Histopathology. 1996 Feb;28(2):129-34 [8834520.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 15;13(5):467-8 [8970478.001]

[Cites] J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):722-7 [10534634.001]

[Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]

[Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]

[Cites] N Engl J Med. 2000 Mar 30;342(13):930-6 [10738051.001]

[Cites] Am J Surg Pathol. 2005 May;29(5):647-52 [15832089.001]

[Cites] Leukemia. 2005 May;19(5):851-5 [15744337.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Clin Infect Dis. 2005 Oct 15;41(8):e76-9 [16163622.001]

[Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]

[Cites] Arch Dermatol. 2005 Oct;141(10):1321-2 [16230579.001]

[Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]

[Cites] J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):558-64 [16284532.001]

[Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]

[Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]

[Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]

[Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]

[Cites] Mod Pathol. 2006 Mar;19(3):438-46 [16444194.001]

[Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]

[Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]

[Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]

[Cites] Am J Surg Pathol. 2003 Mar;27(3):293-302 [12604885.001]

[Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]

[Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]

[Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]

[Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]

[Cites] Hum Pathol. 2003 Sep;34(9):950-4 [14562294.001]

[Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]

[Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]

[Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]

[Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):371-6 [11317081.001]

[Cites] Arch Pathol Lab Med. 2001 Sep;125(9):1246-8 [11520284.001]

[Cites] AIDS. 2001 Sep 28;15(14):1913-5 [11579268.001]

[Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]

[Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]

[Cites] Cancer. 2002 Mar 1;94(5):1500-6 [11920507.001]

[Cites] Arch Pathol Lab Med. 2002 Jun;126(6):738-41 [12033970.001]

[Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]

(PMID = 18042692.001).

[ISSN] 1472-4146

[Journal-full-title] Journal of clinical pathology

[ISO-abbreviation] J. Clin. Pathol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Number-of-references] 80

[Other-IDs] NLM/ PMC2095580

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.

BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.

In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.

Kaposi's sarcoma (KS) lesions are now causally associated with KSHV/HHV-8 but whether African ARL shows this association is not clear.

Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.

OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.

The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.

Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.

These findings were not related to age, sex or type of lymphoma.

There was no association of HHV-8 with the lymphoma cells.

CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.

[MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology

[MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]

[Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]

[Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]

[Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]

[Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]

[Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]

[Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]

[Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]

[Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]

[Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]

[Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]

[Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]

[Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]

[Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]

[Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]

[Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]

[Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]

[Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]

[Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]

[Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]

[Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]

[Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]

[Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]

[Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]

[Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]

[Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]

[Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]

[Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]

[Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]

[Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]

[Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]

[Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]

[Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]

[Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]

[Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]

[Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]

(PMID = 16916294.001).

[ISSN] 1729-0503

[Journal-full-title] African health sciences

[ISO-abbreviation] Afr Health Sci

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Uganda

[Other-IDs] NLM/ PMC1831982

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Images in cardiovascular medicine. Complementary role of multimodality imaging in the evaluation of intracardiac lymphoma in an HIV-infected man.

[MeSH-major] Burkitt Lymphoma / diagnosis. Heart Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

Genetic Alliance. consumer health - HIV.

HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17389272.001).

[ISSN] 1524-4539

[Journal-full-title] Circulation

[ISO-abbreviation] Circulation

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Burkitt lymphoma with cutaneous involvement.

[MeSH-major] Burkitt Lymphoma / pathology. Lymphoma, AIDS-Related / pathology. Skin / pathology

[MeSH-minor] AIDS-Related Opportunistic Infections / etiology. Adult. Axilla. Candidiasis / etiology. Cellulitis / diagnosis. Diagnostic Errors. Disease Progression. Fatal Outcome. Fungemia / etiology. Humans. Male

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18700117.001).

[ISSN] 1087-2108

[Journal-full-title] Dermatology online journal

[ISO-abbreviation] Dermatol. Online J.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Burkitt's lymphoma of the duodenum in a patient with AIDS.

Non-Hodgkin's lymphoma of B-cell type is the second most common neoplasm after Kaposi's sarcoma, among patients with human immunodeficiency virus infection.

Most non-Hodgkin's lymphoma cases that are associated with acquired immunodeficiency syndrome involve extranodal sites, especially the digestive tract and the central nervous system.

We report a case of primary lymphoma of the duodenum in a patient with AIDS.

A complete diagnostic study including histological, immunohistochemical and virological analyses showed high-grade B-cell Burkitt's lymphoma.

[MeSH-major] Burkitt Lymphoma / diagnosis. Duodenal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - Intestinal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17653472.001).

[ISSN] 0037-8682

[Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical

[ISO-abbreviation] Rev. Soc. Bras. Med. Trop.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary meningeal Burkitt-type lymphoma presenting as the first clinical manifestation of acquired immunodeficiency syndrome.

The purpose of this study is to report a rare case of primary meningeal high grade Burkitt-type lymphoma presenting as the first clinical manifestation of acquired immunodeficiency syndrome.

Some hours after the surgery, the patient developed hemispheric cerebral edema and intracranial hypertension syndrome.

Screening blood tests diagnosed human immunodeficiency virus infection.

Pathological studies diagnosed Burkitt-type lymphoma.

[MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16917629.001).

[ISSN] 0004-282X

[Journal-full-title] Arquivos de neuro-psiquiatria

[ISO-abbreviation] Arq Neuropsiquiatr

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Brazil

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Impact of infection with human immunodeficiency virus-1 (HIV) on the risk of cancer among children in Malawi - preliminary findings.

METHODS: Only children with a cancer diagnosis were included.

Odds ratios (OR) for being HIV positive were estimated for each cancer type (with adjustment for age (<5 years, >/= 5 years) and sex) using children with other cancers and non-malignant conditions as a comparison group (excluding the known HIV-associated cancers, Kaposi sarcoma and lymphomas, as well as children with other haematological malignancies or with confirmed non-cancer diagnoses).

Infection with HIV was associated with Kaposi sarcoma (29 cases; OR = 93.5, 95% CI 26.9 to 324.4) and with non-Burkitt, non-Hodgkin lymphoma (33 cases; OR = 4.4, 95% CI 1.1 to 17.9) but not with Burkitt lymphoma (269 cases; OR = 2.2, 95% CI 0.8 to 6.4).

CONCLUSIONS: In this study, only Kaposi sarcoma and non-Burkitt, non-Hodgkin lymphoma were associated with HIV infection.

The endemic form of Burkitt lymphoma, which is relatively frequent in Malawi, was not significantly associated with HIV.

While the relatively small numbers of children with other cancers, together with possible limitations of diagnostic testing may limit our conclusions, the findings may suggest differences in the pathogenesis of HIV-related malignancies in different parts of the world.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Sarcoma. 2009;2009:741975 [19503800.001]

[Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]

[Cites] J Infect Dis. 2007 Mar 15;195(6):895-904 [17299721.001]

[Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]

[Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] Oncologist. 1999;4(4):309-17 [10476542.001]

[Cites] Br J Cancer. 1998 Dec;78(11):1521-8 [9836488.001]

[Cites] J Natl Cancer Inst Monogr. 1998;(23):31-5 [9709300.001]

[Cites] J Clin Oncol. 1998 May;16(5):1729-35 [9586885.001]

[Cites] Arch Dis Child. 1997 Apr;76(4):330-3 [9166025.001]

[Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]

[Cites] AIDS. 1996 Jun;10(6):643-7 [8780819.001]

[Cites] Arch Dis Child. 1995 Aug;73(2):100-4; discussion 104-5 [7574850.001]

[Cites] East Afr Med J. 1995 Jan;72(1):25-9 [7781551.001]

[Cites] N Engl J Med. 1995 Jan 5;332(1):12-8 [7990860.001]

[Cites] Pediatr Pathol. 1986;6(2-3):181-97 [3822934.001]

[Cites] East Afr Med J. 1979 Jan;56(1):15-21 [436701.001]

[Cites] Trans R Soc Trop Med Hyg. 2004 Sep;98(9):544-52 [15251404.001]

[Cites] JAMA. 2003 May 14;289(18):2393-9 [12746363.001]

[Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]

[Cites] Eur J Cancer. 2001 Jul;37(10):1188-201 [11423251.001]

[Cites] Pediatr Infect Dis J. 2001 May;20(5):518-21 [11368110.001]

[Cites] Trop Med Int Health. 2001 Apr;6(4):296-304 [11348520.001]

[Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]

[Cites] J Clin Oncol. 2000 Nov 15;18(22):3854-61 [11078499.001]

[Cites] J Intern Med. 2000 Sep;248(3):171-83 [10971784.001]

[Cites] JAMA. 2000 Jul 12;284(2):205-9 [10889594.001]

[Cites] PLoS One. 2008;3(6):e2505 [18560562.001]

(PMID = 20152034.001).

[ISSN] 1750-9378

[Journal-full-title] Infectious agents and cancer

[ISO-abbreviation] Infect. Agents Cancer

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC2831850

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

These viruses are closely related to Epstein-Barr virus (EBV, Human herpesvirus 4) and share similar genomic organization and biological properties.

Recent evidence indicates that nonhuman primate LCVs can immortalize B cells from genetically related species, suggesting a close evolutionary relationship between these viruses and their respective hosts.

Early work with EBV in tamarins and owl monkeys revealed that cross species transmission of lymphocryptoviruses from the natural to inadvertent host may be associated with oncogenesis and the development of malignant lymphoma.

Moreover, simian LCVs have the ability to induce malignant lymphomas in immunodeficient hosts and have been associated with posttransplantation lymphoproliferative disease in cynomolgus macaques undergoing solid organ transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]

[Cites] Nephrology (Carlton). 2006 Aug;11(4):355-66 [16889577.001]

[Cites] Transpl Immunol. 2007 Apr;17(3):203-10 [17331848.001]

[Cites] BMC Cancer. 2007;7:35 [17324269.001]

[Cites] Annu Rev Immunol. 2007;25:587-617 [17378764.001]

[Cites] Adv Cancer Res. 2007;97:81-109 [17419942.001]

[Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7606-11 [17446270.001]

[Cites] J Gen Virol. 2007 Aug;88(Pt 8):2129-36 [17622614.001]

[Cites] J Exp Med. 2007 Aug 6;204(8):1863-73 [17620360.001]

[Cites] J Clin Virol. 2007 Oct;40(2):156-9 [17703994.001]

[Cites] J Virol. 2007 Oct;81(20):11236-45 [17686859.001]

[Cites] Comp Med. 2008 Feb;58(1):31-42 [19793454.001]

[Cites] Intervirology. 1989;30(6):346-50 [2559902.001]

[Cites] Dent Today. 1989 Aug;8(8):18-9, 50 [2561057.001]

[Cites] Am J Pathol. 1990 Apr;136(4):751-8 [1691592.001]

[Cites] Lancet. 1999 Nov 13;354(9191):1698-9 [10568575.001]

[Cites] J Virol. 2000 Jan;74(1):379-89 [10590127.001]

[Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):163-71 [10659055.001]

[Cites] Rev Med Virol. 2000 Mar-Apr;10(2):83-100 [10713596.001]

[Cites] J Virol. 2000 Jul;74(13):5921-32 [10846073.001]

[Cites] J Clin Microbiol. 2000 Sep;38(9):3219-25 [10970361.001]

[Cites] Comp Med. 2000 Feb;50(1):59-68 [10987671.001]

[Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):489-97 [11313007.001]

[Cites] AIDS Res Hum Retroviruses. 2001 May 20;17(8):745-51 [11429114.001]

[Cites] J Med Virol. 2001 Sep;65(1):114-20 [11505452.001]

[Cites] Blood. 2001 Oct 1;98(7):2193-9 [11568007.001]

[Cites] Biomed Pharmacother. 2001 Sep;55(7):348-52 [11669495.001]

[Cites] J Virol. 2002 Jan;76(1):421-6 [11739708.001]

[Cites] Transplantation. 2002 May 15;73(9):1431-9 [12023621.001]

[Cites] J Gen Virol. 2002 Jul;83(Pt 7):1621-33 [12075080.001]

[Cites] Vet Pathol. 2002 Jan;39(1):42-55 [12102218.001]

[Cites] J Virol. 2002 Dec;76(23):12055-68 [12414947.001]

[Cites] Semin Cancer Biol. 2002 Dec;12(6):431-41 [12450729.001]

[Cites] Crit Rev Oncol Hematol. 2002 Dec;44(3):203-15 [12467961.001]

[Cites] Folia Microbiol (Praha). 2003;48(3):291-318 [12879740.001]

[Cites] Pediatr Pulmonol. 2003 Nov;36(5):447-9 [14520729.001]

[Cites] Virus Res. 2004 Feb;99(2):187-92 [14749184.001]

[Cites] J Virol. 2004 Apr;78(7):3455-61 [15016868.001]

[Cites] Leuk Lymphoma. 2004 Jan;45(1):161-9 [15061214.001]

[Cites] Biochem Biophys Res Commun. 2004 Jun 18;319(1):221-9 [15158465.001]

[Cites] Blood. 2004 Sep 1;104(5):1482-9 [15150077.001]

[Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]

[Cites] Laryngoscope. 1972 Nov;82(11):2049-58 [4343097.001]

[Cites] Nat New Biol. 1973 Mar 7;242(114):28-30 [4632528.001]

[Cites] Am J Vet Res. 1973 May;34(5):677-80 [4634067.001]

[Cites] Ann Clin Lab Sci. 1974 Mar-Apr;4(2):109-14 [4362218.001]

[Cites] Bibl Haematol. 1970;(36):706-13 [4376392.001]

[Cites] Int J Cancer. 1974 Nov 15;14(5):580-8 [4142471.001]

[Cites] Proc Natl Acad Sci U S A. 1975 Apr;72(4):1477-81 [165511.001]

[Cites] Lab Anim Sci. 1976 Dec;26(6 Pt 2):1104-12 [190472.001]

[Cites] Arch Otolaryngol. 1978 Aug;104(8):427-30 [209772.001]

[Cites] Int J Cancer. 1983 Jan 15;31(1):91-7 [6299974.001]

[Cites] Scand J Infect Dis Suppl. 1982;36:15-23 [6304867.001]

[Cites] Int J Cancer. 1986 Sep 15;38(3):425-32 [3017870.001]

[Cites] Cancer. 1987 Apr 15;59(8):1419-29 [3815312.001]

[Cites] AIDS Res. 1986 Dec;2 Suppl 1:S167-76 [3030345.001]

[Cites] J Comp Pathol. 1987 Mar;97(2):159-69 [3036914.001]

[Cites] J Oral Pathol Med. 1990 Apr;19(4):192-4 [2164104.001]

[Cites] J Virol. 1992 Jan;66(1):122-31 [1309242.001]

[Cites] Arch Virol. 1992;123(3-4):425-49 [1562239.001]

[Cites] Histopathology. 1992 May;20(5):387-95 [1316871.001]

[Cites] Hum Pathol. 1993 Jun;24(6):657-67 [8389318.001]

[Cites] Blood. 1994 Jul 15;84(2):397-402 [8025268.001]

[Cites] Clin Exp Dermatol. 1994 Jul;19(4):335-40 [7955479.001]

[Cites] J Virol. 1995 Jul;69(7):3987-94 [7539502.001]

[Cites] J Infect Dis. 1995 Aug;172(2):535-9 [7622899.001]

[Cites] Carcinogenesis. 1995 Aug;16(8):1879-85 [7634418.001]

[Cites] Eur J Cancer. 1995 Oct;31A(11):1875-8 [8541116.001]

[Cites] Leuk Lymphoma. 1995 Nov;19(5-6):401-6 [8590839.001]

[Cites] Oncogene. 1996 Nov 21;13(10):2243-54 [8950992.001]

[Cites] Blood. 1997 Mar 1;89(5):1665-77 [9057649.001]

[Cites] Science. 1997 Jun 27;276(5321):2030-3 [9197263.001]

[Cites] Int J Cancer. 1997 Jul 3;72(1):160-5 [9212238.001]

[Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]

[Cites] J Virol. 1998 Apr;72(4):3205-12 [9525646.001]

[Cites] Nature. 1998 Oct 1;395(6701):462-9 [9774102.001]

[Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]

[Cites] Immunol Lett. 1999 May 3;68(1):147-54 [10397170.001]

[Cites] Blood. 1999 Sep 15;94(6):2090-101 [10477739.001]

[Cites] J Virol. 1999 Oct;73(10):8867-72 [10482645.001]

[Cites] J Virol. 1999 Nov;73(11):9206-12 [10516028.001]

[Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]

[Cites] Expert Rev Mol Med. 2004 Nov 5;6(23):1-16 [15541197.001]

[Cites] Rev Med Virol. 2005 Jan-Feb;15(1):3-15 [15386591.001]

[Cites] Exp Anim. 2005 Jan;54(1):101-5 [15725687.001]

[Cites] J Virol. 2005 Aug;79(15):10069-72 [16014968.001]

[Cites] Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 [15979320.001]

[Cites] J Virol. 2005 Oct;79(20):12681-91 [16188971.001]

[Cites] Microsc Res Tech. 2005 Nov;68(3-4):168-75 [16276515.001]

[Cites] Am J Transplant. 2005 Dec;5(12):2901-6 [16303003.001]

[Cites] Expert Rev Anti Infect Ther. 2006 Feb;4(1):77-89 [16441211.001]

[Cites] Am J Transplant. 2006 Mar;6(3):569-76 [16468968.001]

[Cites] J Immunol. 2006 Mar 15;176(6):3391-401 [16517707.001]

[Cites] J Biol Chem. 2006 Apr 7;281(14):9163-9 [16469740.001]

[Cites] Reprod Toxicol. 2006 May;21(4):436-45 [16580943.001]

[Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7065-70 [16606841.001]

[Cites] Ann Hematol. 2006 Jul;85(7):478-84 [16586109.001]

(PMID = 19793458.001).

[ISSN] 1532-0820

[Journal-full-title] Comparative medicine

[ISO-abbreviation] Comp. Med.

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / RR00168; United States / NCRR NIH HHS / RR / RR16020; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCRR NIH HHS / RR / U42 RR016020

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Viral

[Other-IDs] NLM/ PMC2703161

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Variable problems in lymphomas: CASE 3. Spontaneous regression of HIV-associated Burkitt's lymphoma of the cecum.

[MeSH-major] Burkitt Lymphoma / pathology. Cecal Neoplasms / pathology. Lymphoma, AIDS-Related / pathology. Neoplasm Regression, Spontaneous

Genetic Alliance. consumer health - HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentOn] J Clin Oncol. 2005 Feb 20;23(6):1152-60 [15718311.001]

(PMID = 16258111.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Case Reports; Comment; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-HIV Agents

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Burkitt's lymphoma: conversion from lymphoma negative to lymphoma positive status over 2 months in a patient with acquired immunodeficiency syndrome (AIDS).

[MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18091062.001).

[ISSN] 1537-453X

[Journal-full-title] American journal of clinical oncology

[ISO-abbreviation] Am. J. Clin. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Burkitt lymphoma and Leishmaniasis in the same tissue sample in an AIDS patient.

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Burkitt Lymphoma / complications. Leishmaniasis, Visceral / complications

[MeSH-minor] Adult. Animals. Antigens, CD20 / analysis. Antiretroviral Therapy, Highly Active. Cough / etiology. DNA-Binding Proteins / analysis. Fever / etiology. Histiocytes / parasitology. Histiocytes / pathology. Humans. Leishmania donovani / growth & development. Lymph Nodes / chemistry. Lymph Nodes / pathology. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / pathology. Male. Neprilysin / analysis

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Leishmaniasis.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16722944.001).

[ISSN] 0309-0167

[Journal-full-title] Histopathology

[ISO-abbreviation] Histopathology

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD20; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; EC 3.4.24.11 / Neprilysin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma.

METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain.

We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database.

Factors associated with overall survival were CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 [95% CI 1.01-5.67]), the international prognostic index score (HR 1.98-3.62 across categories) and Burkitt histological subtypes (HR 2.56 [95% CI 1.13-5.78]).

The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count.

[MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17926647.001).

[ISSN] 1359-6535

[Journal-full-title] Antiviral therapy

[ISO-abbreviation] Antivir. Ther. (Lond.)

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.

Human immunodeficiency virus-infected patients are at an increased risk for developing both Hodgkin and non-Hodgkin lymphoma when compared with the general population.

With the remarkable decrease in the incidence of opportunistic infections since the availability of highly active antiretroviral therapy (HAART), acquired immune deficiency syndrome-related lymphoma (ARL) is now the second most common cancer associated with human immunodeficiency virus after Kaposi sarcoma.

Apart from the contribution of HAART, this improvement in prognosis can also be attributed to new initiatives in treatment of these patients, such as the use of effective infusional regimens, the feasibility of high-dose therapy with peripheral stem cell rescue for relapsed or refractory disease, and better supportive care.

Nonetheless, several controversial issues persist, including the optimal timing of HAART with combination chemotherapy, the role of rituximab when incorporated into treatment regimens, and the optimal therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma.

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / physiopathology

[MeSH-minor] AIDS-Related Opportunistic Infections. Drug Administration Schedule. Humans. Incidence. Peripheral Blood Stem Cell Transplantation. Prevalence. Prognosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16020424.001).

[ISSN] 0007-9235

[Journal-full-title] CA: a cancer journal for clinicians

[ISO-abbreviation] CA Cancer J Clin

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 52

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma.

In contrast to adults, autologous stem cell transplantation (ASCT) as part of the salvage strategy after high-dose chemo/radiotherapy in human immunodeficiency virus (HIV) related Non-Hodgkin lymphoma (NHL) is not yet established for children.

We report on a 13-year patient with congenital HIV infection and refractory Burkitt lymphoma, who was successfully treated by high-dose therapy (HDT) including rituximab followed by ASCT.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / therapy. Hematopoietic Stem Cell Transplantation. Lymphoma, AIDS-Related / therapy. Transplantation Conditioning

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2007 Wiley-Liss, Inc

(PMID = 16685736.001).

[ISSN] 1545-5009

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related cancer and severity of immunosuppression in persons with AIDS.

BACKGROUND: The incidence of Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer has been declining among persons with AIDS.

We investigated the association between cancer risk and CD4 cell count among such persons.

METHODS: Data from US AIDS registries were linked to local cancer registry data.

Cancer incidence per 100,000 person-years was determined for the 4-27 months from the onset of AIDS from January 1, 1990, through December 31, 1995--before highly active antiretroviral therapy (HAART) became available--and from January 1, 1996, through December 31, 2002.

The relationships between CD4 count at AIDS onset and cancer incidence were assessed by proportional hazards models.

RESULTS: Among 325,516 adults with AIDS, the incidence of Kaposi sarcoma was lower in 1996-2002 (334.6 cases per 100,000 person-years) than in 1990-1995 (1838.9 cases per 100,000 person-years), and the incidence of non-Hodgkin lymphoma followed a similar pattern (i.e., 390.1 cases per 100,000 person-years in 1996-2002 and 1066.2 cases per 100,000 person-years in 1990-1995).

In 1996-2002, for each decline in CD4 cell count of 50 cells per microliter of blood, increased risks were found for Kaposi sarcoma (hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.33 to 1.50), for central nervous system non-Hodgkin lymphoma subtypes (HR = 1.85, 95% CI = 1.58 to 2.16), and for non-central nervous system diffuse large B-cell lymphoma (HR = 1.12, 95% CI = 1.04 to 1.20) but not for non-central nervous system Burkitt lymphoma (HR = 0.93, 95% CI = 0.81 to 1.06).

After adjustment for age, race, and sex or mode of HIV exposure, the risks for Kaposi sarcoma (RR = 0.22, 95% CI = 0.20 to 0.24) and for non-Hodgkin lymphoma (RR = 0.40, 95% CI = 0.36 to 0.44) were lower in the period of 1996-2002 than in 1990-1995.

CONCLUSIONS: Both before and after HAART was available, CD4 count was strongly associated with risks for Kaposi sarcoma and non-Hodgkin lymphoma but not for cervical cancer and Burkitt lymphoma.

The decreasing incidences of most AIDS-associated cancers in persons with AIDS during the 1990s are consistent with improving CD4 counts after HAART introduction in 1996.

[MeSH-major] Acquired Immunodeficiency Syndrome / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology. Sarcoma, Kaposi / immunology

[MeSH-minor] Adolescent. Adult. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / immunology. Burkitt Lymphoma / virology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Female. Humans. Male. Middle Aged. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / immunology. Uterine Cervical Neoplasms / virology

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17565153.001).

[ISSN] 1460-2105

[Journal-full-title] Journal of the National Cancer Institute

[ISO-abbreviation] J. Natl. Cancer Inst.

[Language] eng

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.

BACKGROUND: Non-Hodgkin lymphoma (NHL) associated with HIV became an AIDS-defining condition early in the epidemic and remains the second most common malignancy in patients with AIDS.

With the advent of highly active antiretroviral therapy (HAART), the incidence and mortality of AIDS-related opportunistic infections and Kaposi's sarcoma has fallen dramatically, this trend is not observed so clearly for NHL.

Our objective was to review the clinical spectrum of patients with AIDS-associated NHL and to analyze the impact of HAART on survival at an oncological tertiary center.

MATERIAL AND METHODS: We reviewed all medical records and histopathologic tissue of patients with HIV-associated NHL seen from January 1990 to September 2007 at the Instituto Nacional de Cancerologia in Mexico City.

Survival or follow-up time was calculated from date of diagnosis to death, or to the date on which the patient was last seen.

RESULTS: Eighty seven HIV-positive patients were diagnosed with NHL (diffuse large B-cell lymphoma n=69; Burkitt-like n=8; pleomorphic large cell n=7; low-grade n=2, and angiocentric n=1).

Overall, 38 patients (43.7%) achieved complete response to NHL therapy, including only 14.3% patients in the non-HAART compared with 57.6% in the HAART group (p < or = 0.0001).

Two patients (7.1%) in the non-HAART were alive compared with 37 (63.8%) in the HAART group (p < or = 0.0001).

[MeSH-major] Cancer Care Facilities / statistics & numerical data. Lymphoma, AIDS-Related / epidemiology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

[MeSH-minor] Acquired Immunodeficiency Syndrome / drug therapy. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Mexico / epidemiology. Middle Aged. Retrospective Studies. Young Adult

Genetic Alliance. consumer health - AIDS-HIV.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19227434.001).

[ISSN] 0034-8376

[Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición

[ISO-abbreviation] Rev. Invest. Clin.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Mexico

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy.

Recent introduction of highly active antiretroviral therapy (HAART) is reported to have reduced the incidence of lymphoma among HIV-infected individuals.

A clinicopathological study was performed on 86 AIDS-related lymphoma patients who were treated in Tokyo area from 1987 to 2005.

The incidence of lymphoma detected by autopsy was 27% (53 cases/198 autopsies).

Diffuse large B cell lymphoma was the most predominant histological subtype throughout the period (78%).

Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users.

Epstein-Barr virus (EBV)-positive lymphoma decreased from 88% in the pre-HAART era to 58% in the HAART era, but did not differ significantly between HAART users (73%) and non-users (74%).

Nodal involvement of lymphoma increased from 14% in the pre-HAART era to 50% in the HAART era; however, central nervous system involvement decreased from 62 to 38%.

Kaposi's sarcoma-associated herpesvirus infection was rare (4%) among all cases.

These data suggest that HAART might play a partial role in these changes, and the alteration in immunological backgrounds, such as EBV prevalence, is suggested as another leading cause of these changes in Japanese AIDS-related lymphoma.

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16697236.001).

[ISSN] 1286-4579

[Journal-full-title] Microbes and infection

[ISO-abbreviation] Microbes Infect.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] France

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related Burkitt lymphoma--a heterogeneous disease?

[MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis. Submandibular Gland Neoplasms / diagnosis

Genetic Alliance. consumer health - AIDS-HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18472158.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Viral; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.

PURPOSE: This article describes and discusses primary Burkitt's lymphoma of the anus which is an extremely rare site of origin.

Histopathology and immunohistology provided evidence of an Epstein-Barr virus-associated Burkitt's lymphoma.

CONCLUSIONS: Because of the AIDS epidemic and the increase of anal malignant pathologies, anal Burkitt's lymphoma may appear more frequently.

Adequate treatment is available for only a small percentage of patients.

[MeSH-major] Anus Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis

[MeSH-minor] Adult. Colostomy. Fatal Outcome. HIV Seropositivity / diagnosis. Herpesvirus 4, Human / isolation & purification. Humans. Male. Rectum / surgery

Genetic Alliance. consumer health - HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - Anal Cancer.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16034658.001).

[ISSN] 0012-3706

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Acquired immunodeficiency syndrome associated with Burkitt's leukemia diagnosed by ileus].

[MeSH-major] Burkitt Lymphoma / diagnosis. Ileus / etiology. Lymphoma, AIDS-Related / diagnosis

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18283903.001).

[ISSN] 0021-5384

[Journal-full-title] Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine

[ISO-abbreviation] Nippon Naika Gakkai Zasshi

[Language] jpn

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.

Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.

The description of an aberrant immunophenotype was the criterion used to define the malignant nature of any CSF cell population.

RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.

This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.

[MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis

[MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

Genetic Alliance. consumer health - AIDS-HIV.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15670248.001).

[ISSN] 1464-2662

[Journal-full-title] HIV medicine

[ISO-abbreviation] HIV Med.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.

OBJECTIVE AND DESIGN: : To retrospectively describe the recovery of cellular immunity and the clinical outcome of 30 patients with HIV-associated Burkitt's lymphoma (HIV-BL), who were treated with the intensive chemotherapy CODOX-M/IVAC and HAART as part of their standard care.

The median CD4 cell count at diagnosis of HIV-BL was 171/ml (range: 4-848) and the plasma HIV viral load was undetectable in five of 29 patients.

Viral load was undetectable in 88% and CD4 cell count more than 200/ml in 58% of patients assessed 6 months after completing chemotherapy, and in 87 and 80% at 12 months, respectively.

CONCLUSION: : The intensive regimen CODOX-M/IVAC, a feasible and effective chemotherapy, is associated with an excellent immunological recovery in patients with HIV-BL on HAART.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy

Genetic Alliance. consumer health - HIV.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20124971.001).

[ISSN] 1473-5571

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The most commonly reported neoplasms of the head and neck region include Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL).

There is also an increased risk of oral squamous cell carcinoma (SCC).

A descriptive cross-sectional study including HIV-infected patients with neoplastic and non-neoplastic lesions was conducted.

The prevalence of neoplastic lesions in this study was 27%; 37 (68%) patients had KS, 9 (17%) had SCC, 7 (13%) had NHL and 1 (2%) had Burkitt's lymphoma.

In this study, the most common malignant neoplasms were KS, SCC and NHL, manifesting in a younger age group than in the non-HIV group of patients.

[MeSH-minor] Adolescent. Adult. Age Factors. Burkitt Lymphoma / epidemiology. Candidiasis, Oral / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cheilitis / epidemiology. Cross-Sectional Studies. Female. Humans. Kenya / epidemiology. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Prevalence. Sarcoma, Kaposi / epidemiology. Sex Factors. Stomatitis, Aphthous / epidemiology. Young Adult

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18783921.001).

[ISSN] 0901-5027

[Journal-full-title] International journal of oral and maxillofacial surgery

[ISO-abbreviation] Int J Oral Maxillofac Surg

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Denmark

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005.

Burkitt lymphoma (BL) is a unique B-cell non-Hodgkin lymphoma with 3 established clinical-epidemiological variants: endemic, sporadic and AIDS-related BL.

Therefore, we examined population-based BL incidence patterns in the United States to determine age-related risk.

The tri/bimodal incidence pattern was present in sensitivity analyses excluding registries with many HIV/AIDS cases and in period-specific, cohort-specific analyses.

[MeSH-major] Burkitt Lymphoma / epidemiology

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2009 UICC.

[Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]

[Cites] Biometrics. 1995 Sep;51(3):874-87 [7548706.001]

[Cites] Am J Epidemiol. 1996 Jan 1;143(1):85-91 [8533751.001]

[Cites] Blood. 1999 Feb 1;93(3):1124 [10025990.001]

[Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]

[Cites] Cancer. 1957 Sep-Oct;10(5):1045-54 [13472655.001]

[Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]

[Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]

[Cites] Ann Intern Med. 1969 Apr;70(4):817-32 [4306129.001]

[Cites] Br J Prev Soc Med. 1971 Nov;25(4):242-4 [5160433.001]

[Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]

[Cites] Eur J Cancer. 1972 Jun;8(3):305-8 [4677829.001]

[Cites] N Engl J Med. 1981 Sep 24;305(13):735-45 [7022215.001]

[Cites] Lancet. 1982 Sep 18;2(8299):631-3 [6125777.001]

[Cites] Biometrics. 1983 Jun;39(2):311-24 [6626659.001]

[Cites] Stat Med. 1987 Jun;6(4):449-67 [3629047.001]

[Cites] Stat Med. 1987 Jun;6(4):469-81 [3629048.001]

[Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]

[Cites] Br J Cancer. 1963 Mar;17:50-5 [14001942.001]

[Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]

[Cites] Nat Rev Microbiol. 2008 Dec;6(12):913-24 [19008891.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2008;:341-8 [19074108.001]

[Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1804-14 [19066264.001]

[Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2256-61 [19622723.001]

[Cites] MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):589-92 [16741494.001]

[Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] MMWR Suppl. 1987 Dec 25;36(7):1S-20S [2826984.001]

[Cites] Annu Rev Public Health. 1991;12:425-57 [2049144.001]

[Cites] Am J Epidemiol. 1987 Oct;126(4):578-86 [3631049.001]

(PMID = 19810101.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z01 CP010176-07; United States / Intramural NIH HHS / / ZIA CP010176-08

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Other-IDs] NLM/ NIHMS146203; NLM/ PMC2818154

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.

PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.

PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).

RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis.

Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use

Genetic Alliance. consumer health - AIDS-HIV.

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - Burkitt's Lymphoma.

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Steroids.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. BLEOMYCIN .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. DEXAMETHASONE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. LEUCOVORIN .

Hazardous Substances Data Bank. METHOTREXATE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] J Clin Oncol. 2005 Nov 20;23(33):8538-40; author reply 8540-1 [16293885.001]

[CommentIn] J Clin Oncol. 2005 Nov 1;23(31):8132-3; author reply 8133-4 [16258119.001]

(PMID = 15883411.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; M-BACOD protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Colorectal lymphoma in the setting of HIV: case report and review of the literature.

The incidence of Burkitt's lymphoma, a rare and aggressive form of non-Hodgkin's lymphoma, remains unaffected by immune reconstitution in HIV-infected individuals.

A flexible sigmoidoscopy with biopsy of the rectum and peripheral blood smear with bone marrow examination revealed immunophenotypic and cytogenic findings diagnostic of Burkitt's lymphoma of the rectum.

[MeSH-major] Burkitt Lymphoma / diagnosis. Colorectal Neoplasms / diagnosis. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Colorectal Cancer.

MedlinePlus Health Information. consumer health - HIV/AIDS.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19265464.001).

[ISSN] 1557-7449

[Journal-full-title] AIDS patient care and STDs

[ISO-abbreviation] AIDS Patient Care STDS

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 18

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genomic imbalances in AIDS-related lymphomas: relation with tumoral Epstein-Barr virus status.

BACKGROUND: The pathologic heterogeneity of AIDS related lymphomas (ARL) reflects several pathogenic mechanisms: chronic antigenic stimulation, Epstein-Barr virus (EBV) infection, and genomic abnormalities.

Genetic abnormalities, known to play a major role in lymphomas of non-immunocompromised patients, are not well characterized in ARL.

Most chromosomal regions affected in HIV-related lymphoma were similar to those already reported in HIV-negative lymphomas.

CONCLUSION: This CGH study allowed the identification of non-random chromosomal alterations in ARL.

The results suggested an inverse relationship between EBV infection (latency II/III), associated with deep acquired immune suppression, and the number of chromosomal alterations which may be explained by a direct role of viral proteins in lymphomagenesis by activation of signalling pathways without needing several genomic alterations.

[MeSH-major] Epstein-Barr Virus Infections / genetics. Lymphoma, AIDS-Related / genetics

[MeSH-minor] Adult. Aged. Burkitt Lymphoma / complications. Burkitt Lymphoma / genetics. Burkitt Lymphoma / immunology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Chromosome Aberrations. Chromosomes, Human / genetics. Clone Cells / immunology. DNA, Viral / genetics. Female. Genes, Viral / genetics. Genes, Viral / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / immunology. Male. Middle Aged. Nucleic Acid Hybridization / methods

Genetic Alliance. consumer health - AIDS-HIV.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17117014.001).

[ISSN] 0269-9370

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / DNA, Viral